Get the Stockscreener App
0.77
4.19%
0.031
Pre-market:
.78
0.01
+1.30%
Tenaya Therapeutics Inc stock is traded at $0.77, with a volume of 2.75M.
It is up +4.19% in the last 24 hours and down -9.67% over the past month.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
See More
Previous Close:
$0.739
Open:
$0.751
24h Volume:
2.75M
Relative Volume:
0.65
Market Cap:
$167.09M
Revenue:
-
Net Income/Loss:
$-90.60M
P/E Ratio:
-1.2285
EPS:
-0.6268
Net Cash Flow:
$-68.88M
1W Performance:
+6.18%
1M Performance:
-9.67%
6M Performance:
-59.47%
1Y Performance:
+51.75%
1-Day Range:
$0.73
$0.77
1-Week Range:
$0.68
$0.78
52-Week Range:
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.77 | 167.09M | 0 | -90.60M | -68.88M | -0.6268 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Tenaya Therapeutics Receives 'Moderate Buy' Rating from Brokerages - National Today
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
Tenaya Therapeutics (TNYA) Stock Analysis Report | Financials & Insights - Benzinga España
TNYA Stock Price, Quote & Chart | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
William Blair analysts confident on Tenaya Therapeutics (TNYA) product pipeline - MSN
Revenue Check: Is Tenaya Therapeutics Inc in a long term uptrendTreasury Yields & Community Consensus Stock Picks - baoquankhu1.vn
Investor Mood: Is Tenaya Therapeutics Inc stock a value trap2026 Levels & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Tenaya Therapeutics (NASDAQ:TNYA) Shares Down 5%Here's What Happened - MarketBeat
TNYA Technical Analysis | Trend, Signals & Chart Patterns | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Pullback Watch: Is Tenaya Therapeutics Inc part of any ETF2026 Levels & Daily Profit Focused Stock Screening - baoquankhu1.vn
symbol__ Stock Quote Price and Forecast - CNN
Tenaya Therapeutics (TNYA) price target increased by 11.11% to 10.20 - MSN
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline - Yahoo Finance
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Tenaya Therapeutics, Inc. (TNYA) reports Q4 EPS of (12c), in line with consensus - MSN
Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus - Insider Monkey
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story - simplywall.st
Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
What is Lifesci Capital's Estimate for TNYA Q1 Earnings? - MarketBeat
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026 - Meyka
TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally - Dailyhunt
Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration - simplywall.st
William Blair reiterates Outperform on Tenaya Therapeutics stock By Investing.com - Investing.com Australia
Leerink Partners reiterates Outperform on Tenaya stock at $2 - Investing.com UK
William Blair reiterates Outperform on Tenaya Therapeutics stock - Investing.com
Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics Reports Promising 2025 Results, Advances Gene Therapy Programs, and Extends Cash Runway Into 2027 - Minichart
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Yahoo Finance
Tenaya Therapeutics: Advancing Genetic Medicines and Small Molecule Therapies for Heart Disease Treatment - Minichart
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Tenaya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027 - TradingView
Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations - MarketBeat
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TNYA: Clinical progress, Alnylam deal, and financing extend cash runway into 2027 - TradingView
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):